← Back to Investor Relations
In the Press
Helio Genomics and Quest Diagnostics
Why This Matters
LiverRight reaches patients and advocates in the liver disease community. This coverage is significant because it highlights a critical gap: 80–90% of at-risk patients currently don't get screened, and HelioLiver addresses this with a simple blood draw.
Article Summary
LiverRight covers the Helio Genomics and Quest Diagnostics partnership, emphasizing that liver cancer incidence has tripled and mortality has doubled, yet 80–90% of at-risk patients don't get screened. The article highlights how HelioLiver combines cell-free DNA methylation analysis, protein biomarkers, and AI to detect cancer signals ‘earlier than imaging alone’ and notes that blood-based liver cancer screening is ‘moving toward mainstream clinical adoption at scale.’